Geron (GERN) Interest Expenses (2010 - 2026)
Geron's (GERN) quarterly Interest Expenses came in at $7.1 million in Q2 2026, down 16.09% year-over-year from $8.5 million in Q2 2025, and little changed quarter-over-quarter from $7.1 million in Q1 2026.
Analysis
Geron (GERN) Interest Expenses (2010 - 2026) Analysis & Trends
Geron has disclosed Interest Expenses across 17 years of filings, most recently posting $7.1 million for Q2 2026.
- In Q2 2026, Interest Expenses fell 16.09% year-over-year to $7.1 million; the TTM figure through Jun 2026 stood at $30.2 million (up 6.2% YoY), while the FY2025 annual figure was $32.7 million, up 76.49% from the prior year.
- Interest Expenses came in at $7.1 million for Q2 2026 at Geron, roughly flat from $7.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $8.7 million in Q4 2024 to a low of $1.5 million in Q1 2022.
- Average Interest Expenses over 5 years is $4.5 million, with a median of $3.2 million recorded in 2024.
- Year-over-year, Interest Expenses surged 275.1% in 2024 and slipped 16.18% in 2025.
- Over 5 years, Interest Expenses stood at $2.0 million in 2022, then gained by 15.76% to $2.3 million in 2023, then surged by 275.1% to $8.7 million in 2024, then fell by 16.18% to $7.3 million in 2025, then slipped by 2.07% to $7.1 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $7.1 million in Q2 2026, $7.1 million in Q1 2026, and $7.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 7.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.15 Mn |
| Mar 31, 2026 | 7.15 Mn |
| Dec 31, 2025 | 7.30 Mn |
| Sep 30, 2025 | 8.64 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | 8.20 Mn |
| Dec 31, 2024 | 8.71 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 1.92 Mn |
| Dec 31, 2022 | 2.01 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 1.58 Mn |
| Mar 31, 2022 | 1.48 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 1.06 Mn |